The recent marketing launch of Gliconorm (5+500 mg association of glibenclamide and metformine), together with Gliben and Gliben F provide specialists in diabetology with a powerful therapeutic weapon for the treatment of Type II diabetes.

Dermatology has become of great interest to Abiogen Pharma with the brilliant success achieved on the antipsoriatic market with Vellutan (obtaining 17% of the antipsoriac market in 2 years) and the excellent results of Kouriles a dermal cosmetic for dermatitis seborrheica.

The recent launch of Condress, a product for the treatment of skin ulcers represents a most promising future in the dermatologic field.